Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Noxopharm Ltd. ( (AU:NOX) ).
Noxopharm Limited has commenced the second part of its HERACLES clinical trial, administering the first dose of SOF-SKN™, a novel drug candidate for autoimmune diseases like cutaneous lupus erythematosus. This phase aims to evaluate the safety and tolerability of SOF-SKN through repeated dosing, reflecting real-world conditions. The trial’s success could enhance Noxopharm’s position in the regulatory approval process and potentially expand the use of SOF-SKN to other autoimmune-related skin diseases, positioning the company to capture a share of the growing global cutaneous lupus market, valued at over US$3.3 billion.
More about Noxopharm Ltd.
Noxopharm Limited is a clinical-stage Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company leverages its proprietary technology platforms, Sofra™ and Chroma™, to enhance mRNA medicines and develop drugs targeting inflammation, autoimmunity, and oncology.
Average Trading Volume: 111,387
Technical Sentiment Signal: Sell
Current Market Cap: A$26.3M
Find detailed analytics on NOX stock on TipRanks’ Stock Analysis page.